🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

218 results for “Merck” Clear

  1. MK-4280A, TRIFLURIDINE, COMBINATIONS, REGORAFENIB

    Merck Sharp and Dohme

    Colorectal Cancer

    phase 3 small molecule active

    1 trial

  2. MK-6194, Placebo for MK-6194

    Merck Sharp and Dohme

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  3. MK-8591A

    Merck Sharp and Dohme

    HIV infection

    phase 3 small molecule active

    1 trial

  4. Microcrystalline cellulose, Sodium Chloride, Magnesium Stearate, MK-0616

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  5. Molnupiravir Matching placebo tablets, molnupiravir

    Merck Sharp and Dohme

    SARS-CoV-2 (COVID-19) infection

    phase 3 small molecule active

    1 trial

  6. Nemtabrutinib, ACALABRUTINIB , Nemtabrutinib, IBRUTINIB

    Merck Sharp and Dohme

    Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  7. OXALIPLATIN , Placebo to MK-3475, CAPECITABINE , CALCIUM FOLINATE , FLUOROURACIL , CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL

    Merck Sharp and Dohme

    Gastric and gastroesophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  8. Olaparib, CISPLATIN , Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED , CARBOPLATIN

    Merck Sharp and Dohme

    Stage IV lung cancer condition

    phase 3 small molecule active

    1 trial

  9. Olaparib, ETOPOSIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pembrolizumab placebo (saline), Olaparib matching placebo (tablet), CARBOPLATIN , CISPLATIN , Olaparib

    Merck Sharp and Dohme

    Participants with Limited Stage-Small Cell Lung Cancer, who have received no prior anticancer therapy for their disease.

    phase 3 small molecule active

    1 trial

  10. Opevesostat, FLUDROCORTISONE, PREDNISOLONE, DEXAMETHASONE ACETATE, HYDROCORTISONE, FLUDROCORTISONE ACETATE, ABIRATERONE ACETATE, DEXAMETHASONE, ABIRATERONE ACETATE, HYDROCORTISONE, HYDROCORTISONE, ENZALUTAMIDE, HYDROCORTISONE, PREDNISONE, PREDNISONE ACETATE, HYDROCORTISONE

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer

    phase 3 small molecule active

    1 trial

  11. PACLITAXEL, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, Placebo to MK-7339 100 mg, Placebo to MK-7339 150 mg, Olaparib, PACLITAXEL ALBUMIN-BOUND

    Merck Sharp and Dohme

    Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  12. PARACETAMOL , -, -, CARBOPLATIN , -, MK-2870, PEMETREXED

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  13. PEMETREXED , KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN , PACLITAXEL , pembrolizumab, CISPLATIN

    Merck Sharp and Dohme

    Metastatic (stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).

    phase 3 small molecule active

    1 trial

  14. PREDNISOLONE , PREDNISONE , -, Ifinatamab Deruxtecan, PARACETAMOL , -, DOCETAXEL , -, -, -

    Merck Sharp and Dohme

    Metastatic Castration-Resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  15. Placebo for MK-0616, Placebo for Ezetimibe, EZETIMIBE , BEMPEDOIC ACID , MK-0616, Placebo for Bempedoic Acid

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  16. Placebo for MK-7240, tulisokibart

    Merck Sharp and Dohme

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  17. Placebo for pembrolizumab, ENZALUTAMIDE , PEMBROLIZUMAB

    Merck Sharp and Dohme

    Metastatic hormone sensitive prostate cancer

    phase 3 small molecule active

    1 trial

  18. Placebo for pembrolizumab, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE , FLUOROURACIL , OXALIPLATIN , CISPLATIN

    Merck Sharp and Dohme

    Gastric and gastric esophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  19. Placebo to Keytruda - Normal Saline Solution, GEMCITABINE, CISPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Cis-eligible Muscle-invasive bladder cancer.

    phase 3 small molecule active

    1 trial

  20. Placebo to MK-7240 (Tulisokibart), tulisokibart

    Merck Sharp and Dohme

    Crohn’s Disease or Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  21. Placebo to MK-7240, tulisokibart, tulisokibart

    Merck Sharp and Dohme

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  22. Placebo to Pembrolizumab, CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Locally Advanced Cervical Cancer

    phase 3 small molecule active

    1 trial

  23. Placebo to doravirine/ islatravir, MK-8591A, Placebo to bictegravir/ emtricitabine/ tenofovir alafenamide, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets

    Merck Sharp and Dohme

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  24. Pneumovax® 23 solution for injection in pre-filled syringe Pneumococcal Polysaccharide Vaccine, V110, Pneumococcal 21-valent Conjugate Vaccine

    Merck Sharp and Dohme

    Pneumococcal disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources